CRISPR Therapeutics AG — Director's Dealing 2021

Oct 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2021-10-15

Reporting Person: Ho Tony W (Executive VP, Head of R&D)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-15	Stock Option (Right to Buy)	$97.00	A	13800	Acquired	2031-10-15	Common Shares (13800)	Direct

Footnotes

F1: This option was granted on October 15, 2021 with respect to 13,800 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 15, 2021.